Clinical Trials
Protocol Number: 26593 Serono protocol # 26593 Rebif new formulation and Add on cladribine/placebo for subject on Rebif with active disease A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Interferon-beta Treatment in Multiple Sclerosis Patients with Active Disease
|
Protocol Number: CAMMS323 CAMMS 323 Treatment with Alemtuzumab for Treatment Naïve MS patients with active disease, diagnosed within the last 5 years A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment – Naïve Patients with Relapsing –Remitting Multiple Sclerosis |
Protocol Number: CAMMS32400507 CAMMS 324 Treatment with Alemtuzumab for Treatment experienced patients who have relapsed on therapy, diagnosed within the last 5 years A Phase 3 , Randomized, Rater – and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three- Times Weekly Subcutaneous Interferon Beta- 1a (Rebif®) in Patients with Relapsing-Remitting Multiple Sclerosis Who have Relapsed On Therapy |
Protocol Number: MS-LAQ-301 Oral laquinimod study for RRMS patients A Multinational, Milticenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily “Oral Administration of Laquinimod 0.6 mg in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) |
Protocol Number: PREMERE™ESCAPE MIGRAINE ESCAPE sponsored study for migraine patients with a PFO
Effect of Septal Closure of Atrial PFO on Events of Migraine with Premere: Escape Migraine Trial |
Protocol Number: 109MS302 BG00012 Biogen sponsored study for patients with RRMS A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis |
|
